Urine Methylation Markers in UTUC
Launched by DUKE UNIVERSITY · Jan 28, 2025
Trial Information
Current as of July 04, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how certain DNA markers found in urine can help with the diagnosis and monitoring of upper tract urothelial cancer (UTUC), which is a type of cancer that affects the part of the urinary system located above the bladder. Researchers will collect urine samples from patients before they have surgery and during follow-up visits to see if these markers can better predict the risk of the cancer coming back after treatment. The samples will be sent to a research lab for analysis, and the results will be compared to traditional tests that look for cancer cells in the urine and tissue samples.
To participate in this study, you need to be at least 18 years old and have a primary diagnosis of upper tract urothelial cancer. Unfortunately, if you do not feel comfortable signing a consent form or have difficulty understanding the study details, you won't be eligible. This trial is not yet recruiting participants, but it aims to gather important information that could improve how doctors diagnose and treat UTUC in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • \>=18 years
- • Primary UTUC
- Exclusion Criteria:
- • Patients who do not understand and/or are unwilling to sign a written informed consent
About Duke University
Duke University, a leading academic and research institution located in Durham, North Carolina, is renowned for its commitment to advancing healthcare through innovative clinical research. With a strong emphasis on interdisciplinary collaboration, Duke conducts a wide array of clinical trials aimed at developing cutting-edge therapies and improving patient outcomes across various medical fields. The university's Clinical Research Institute provides comprehensive support for trial design, implementation, and regulatory compliance, ensuring that all research adheres to the highest ethical and scientific standards. Duke’s dedication to translating research findings into effective clinical practices underscores its role as a pivotal contributor to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Durham, North Carolina, United States
Patients applied
Trial Officials
Michael Abern, MD
Principal Investigator
Duke University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported